Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Phase III Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression

GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration through the vial or device self-administration in patients with disseminated breast cancer HER2.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Trastuzumab Injectable Solution; Drug: Trastuzumab Injectable Product; Drug: Trastuzumab Injection

Detailed Description

Approximately 195 patients will be included to receive subcutaneous trastuzumab a fixed dose of 600 mg every 3 weeks for 4 cycles (2 administered from the injection of a vial with a syringe and 2 with the injection device). Following administration of these four cycles, the patient will decide whether or not to continue with the subcutaneous formulation of trastuzumab every 3 weeks until progression (out of the study). Since the randomization in the study until the start with subcutaneous trastuzumab, patients will receive a treatment cycle of intravenous trastuzumab as usual.

Main objective: Proportion of patients indicate a preference for the use of subcutaneous vs intravenous trastuzumab.

This principal primary objective will be analyzed with the answers to questionnaire of experiences and preferences of the patients (Principal endpoint) The duration of the study has been estimated after 34 months.

• Study Type: Interventional
• Enrollment (Actual): 166
• Phase: Phase 3

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain, 08003
    • Hospital del Mar
  • Barcelona, Spain, 08036
    • Hospital Clinic I Provincial
  • Barcelona, Spain, 08916
    • Hospital Germans Trias i Pujol
  • Granada, Spain, 18014
    • Hospital Universitario Virgen de las Nieves
  • Lleida, Spain, 25198
    • Hospital Universitario Arnau de Vilanova de Lleida
  • Lugo, Spain, 27004
    • Hospital Universitario Lucus Augusti
  • Madrid, Spain, 28006
    • Hospital Universitario La Princesa
  • Madrid, Spain, 28007
    • Hospital General Universitario Gregorio Maranon
  • Madrid, Spain, 28021
    • Hospital Universitario 12 de octubre
  • Salamanca, Spain, 37007
    • Hospital Universitario de Salamanca
  • Sevilla, Spain, 41013
    • Hospital Universitario Virgen del Rocio
  • Sevilla, Spain, 41009
    • Hospital Universitario Virgen De La Macarena
  • Toledo, Spain, 45004
    • Hospital Virgen De La Salud
  • Valencia, Spain, 46010
    • Hospital Clinico Universitario de Valencia
  • Zaragoza, Spain, 50009
    • Hospital Universitario Miguel Servet
  • Ávila, Spain, 05004
    • Hospital Nuestra Senora de Sonsoles
  • Barcelona
    • Granollers, Barcelona, Spain, 08402
      • Hospital General Universitario de Granollers
    • Mataró, Barcelona, Spain, 08304
      • Hospital de Mataro
    • Sant Joan Despí, Barcelona, Spain, 08970
      • Hospital Sant Joan Despi Moises Broggi
  • Cáceres
    • Plasencia, Cáceres, Spain, 10600
      • Hospital Virgen del Puerto de Plasencia
  • Illes Balears
    • Manacor, Illes Balears, Spain, 07500
      • Hospital de Manacor
  • Madrid
    • Fuenlabrada, Madrid, Spain, 28924
      • Hospital Universitario de Fuenlabrada
    • Leganés, Madrid, Spain, 28911
      • Hospital Universitario Severo Ochoa
    • Pozuelo De Alarcón, Madrid, Spain, 28223
      • Hospital Univesitario Quirón Madrid
  • Murcia
    • Cartagena, Murcia, Spain, 30202
      • Hospital Universitario Santa Lucía
  • Málaga
    • Marbella, Málaga, Spain, 29603
      • Hospital Costa del Sol
  • Tarragona
    • Reus, Tarragona, Spain, 43201
      • Hospital Universitario San Joan de Reus

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Woman, 18 years old or upper.

• Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive histologically confirmed. The criteria for positivity HER 2 are:

  1. immuno-histochemistry (IHC) 3+ (>10% of tumor cells with complete and intense membrane staining)
  2. IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2 amplification (*)
  3. FISH / CISH / SISH + for HER 2 amplification (*) (*) Defined as the ratio of copies of HER 2/neu and copies of centromere of chromosome 17 (CEP17)> 2.2, or a number of copies of HER 2/neu> 6, as per local laboratory criteria.
• Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at least 4 months.
• No evidence of disease progression (clinical and / or radiological) for at least 4 months before inclusion in the study and with a life expectancy of at least 3 months.
• Adequate performance status: Eastern Cooperative Oncology Group (ECOG) <2.
• Adequate bone marrow function, liver and kidney
• Proper cardiac function (LVEF within normal limits the center, measured by echocardiography or MUGA).
• The patient must have been informed of the study and must sign and date informed consent document for entry into the trial.
• The patient must be willing and able to comply with study procedures and be available to answer the study questionnaires.

Exclusion Criteria:

• Patients with no advanced breast cancer.
• Breast cancer patients with tumors HER 2-negative.
• The patient has another active malignancy other than breast adenocarcinoma; are excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia. Patients with a history of malignancy, if they bear> 5 years without evidence of disease could be included.
• The patient has uncontrolled brain metastases.
• Concomitant administration, or in the 4 weeks prior to study entry, of other experimental treatment.
• Known hypersensitivity to trastuzumab or to any of its components.
• Patients with severe dyspnea at rest or requiring supplemental oxygen.
• Heart disease or serious medical pathological prevent trastuzumab administration: documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, clinically significant valvular disease, history of myocardial infarction or evidence of transmural infarction on ECG or hypertension poorly controlled.
• Presence of any concomitant serious systemic disease that is incompatible with the study (at the discretion of the investigator).
• The patient is pregnant or lactating. Women of childbearing potential should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier method (condom or diaphragm) also used in conjunction with spermicidal cream, total abstinence or surgical sterilization, during treatment with the study drugs and for 6 months following the end of treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: T-IV + T-SC vial + T-SC device; Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.	Drug: Trastuzumab Injectable Solution; Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.; Other Names: Herceptin; Drug: Trastuzumab Injectable Product; Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles; Other Names: Herceptin; Drug: Trastuzumab Injection; Powder for concentrate for solution for infusion. 1 cycle; Other Names: Herceptin
Experimental: Arm B: T-IV + T-SC device + T-SC vial; Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.	Drug: Trastuzumab Injectable Solution; Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.; Other Names: Herceptin; Drug: Trastuzumab Injectable Product; Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles; Other Names: Herceptin; Drug: Trastuzumab Injection; Powder for concentrate for solution for infusion. 1 cycle; Other Names: Herceptin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference	The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.	Up to 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference	The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.	Up to 12 weeks
Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference	The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.	Up to 12 weeks
Percentage of Medical Staff Subcutaneous Device vs. Vial Preference	The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.	Up to 12 weeks
Patient Time in Healthcare Unit and Sitting in Chair/Bed	Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit. Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.	An average of 4 months
The Number of Participants Who Experienced Adverse Events (AE)	Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.	Through study treatment, an average of 12 weeks

Collaborators and Investigators

• Sponsor: Spanish Breast Cancer Research Group

Publications and helpful links

General Publications

• Ciruelos EM, Montano A, Rodriguez CA, Gonzalez-Flores E, Lluch A, Garrigos L, Quiroga V, Anton A, Malon D, Chacon JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Echarri MJ, Munoz M, Pascual T, Amigo Y, Casas M, Carrasco E, Casas A. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23.

Helpful Links

• Sponsor's web

Study record dates

Study Major Dates

• Study Start (Actual): September 18, 2013
• Primary Completion (Actual): November 30, 2016
• Study Completion (Actual): April 30, 2018

Study Registration Dates

• First Submitted: June 7, 2013
• First Submitted That Met QC Criteria: June 7, 2013
• First Posted (Estimate): June 11, 2013

Study Record Updates

• Last Update Posted (Actual): April 5, 2023
• Last Update Submitted That Met QC Criteria: April 4, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Advanced Breast Cancer; HER2 positive; Subcutaneous trastuzumab; Intravenous trastuzumab
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Trastuzumab
• Other Study ID Numbers: GEICAM/2012-07; 2012-004928-38 (EudraCT Number)